Form 8.3 - The Vanguard Group, Inc.: Sanofi (1503367)
02 12월 2022 - 12:09AM
UK Regulatory
The Vanguard Group, Inc. ( IRSH) Form 8.3 - The Vanguard Group,
Inc.: Sanofi 01-Dec-2022 / 15:09 GMT/BST Dissemination of a
Regulatory Announcement, transmitted by EQS Group. The issuer is
solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Ap19
FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE
IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY
PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR
MORE 1. KEY INFORMATION
Name of person dealing (Note 1) The Vanguard Group, Inc.
Company dealt in Sanofi
Class of relevant security to which the dealings being disclosed relate (Note 2) Ordinary Shares
Date of dealing 29 November 2022
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
Numbers (%) Numbers (%)
(1) Relevant securities 41,259,671 3.26%
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total 41,259,671 3.26%
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
Numbers (%) Numbers (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
Ap20
1. Dealings (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
(b) Derivatives transactions (other than options
transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
Not Applicable
(c) Options transactions in respect of existing relevant
securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities to Type, e.g. Option money paid/
purchasing, varying which the option relates Exercise American, Expiry received per unit
e.g. call etc. (Note 7) price European etc. date (Note 5)
option
Not
Applicable
(ii) Exercising
Product name, Exercise price per unit (Note 5)
Number of securities
e.g. call option
Not Applicable
(e) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Price per unit
Details
(Note 8) (if applicable) (Note 5)
Not Applicable
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person
relating to the voting rights of any relevant securities under any option referred to on this form or relating to the
voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on
this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 01 December 2022
Contact name Shawn Acker
Telephone number 001-610-669-8989
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)
-----------------------------------------------------------------------------------------------------------------------
Category Code: RET - Sanofi
TIDM: IRSH
LEI Code: 5493002789CX3L0CJP65
Sequence No.: 205631
EQS News ID: 1503367
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1503367&application_name=news
(END) Dow Jones Newswires
December 01, 2022 10:09 ET (15:09 GMT)
Sanofi (LSE:0A2V)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Sanofi (LSE:0A2V)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
